Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center

Comments

Scientists Identify Unique Genomic Features in Testicular Cancer

quotesThese findings are an example of the power of genomic sequencing and bioinformatic analysis - with a…quotes

member-photo

Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center Professor of Medicine, Yale School of Medicine New Haven, CT 06520

Comments

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

quotesFirst approval for a biosimilar in solid tumor usage! This should help bring down the cost of bev b…quotes

member-photo

Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signature Program Laurence S. and Jean J. DeLynn Chair of Oncology

Comments

Study Examines 'Watch-And-Wait' Approach for People with Rectal Cancer

quotesThis is a very interesting study that opens the door to prospective investigation of a randomized tr…quotes

member-photo

Ted Okon

Executive Director Community Oncology Alliance

Comments

Cancer Drug Prices Are So High That Doctors Will Test Cutting Doses

quotesThis seems to be band-aiding the drug price issue, which near the root are the increasing discounts …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

Value-Based Oncology Care an Imperfect Proposition Still

quotesThe developers of Value Metric Frameworks continue to struggle to make them relevant and also to mak…quotes

member-photo

H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Comments

Roche Presents Data From Global Phase III Study Showing Significant Clinical Benefit Of Alecensa (Alectinib) In Later-line Advanced ALK-Positive Lung Cancer

quotesThe results of the ALUR trial are impressive but not surprising at all. We should expect a second g…quotes

member-photo

Winston Wong, PharmD

President, W-Squared Group

Comments

Take the Generic, Patients Are Told. Until They Are Not.

quotesThe rationale is pretty simple. The branded drugs are now presenting deep rebate discounts, and brin…quotes

member-photo

Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst

Comments

U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

quotesI am excited to be joining the editorial board on OBR; I have been a fan of the publication since it…quotes

member-photo

Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One

No comments to show!

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology Department of Medicine,Cedars-Sinai Medical Center Associate Director for Academic Program Development Samuel Oschin Comprehensive Cancer Institute Professor of Medicine and Urology, Emeritus David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology

Comments

Bayer Secures One-Two Treatment For Liver Cancer After EU Approval

quotesAfter a decade with only sorafenib for advanced HCC, it is refreshing to have several promising new …quotes

member-photo

Jeff Patton, M.D.

CEO Tennessee Oncology

Comments

New Mexico Physician Chosen as AMA President-elect

quotesThis is great news for community oncology. Barbara will be a great champion for us and the value we…quotes

member-photo

Thomas Marsland, MD

Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Comments

At $475,000, New Cancer Drug Raises Thorny Questions About Drug Pricing — And Value

quotesWOW...that is a hunk of change...BUT it would appear that Novartis is at least following some of the…quotes

member-photo

William Harwin MD

Florida Cancer Specialists President and Managing Partner

Comments

Memorial Sloan Kettering to Offer DigniCap® Scalp Cooling Device in New York Metro Area Locations

quotesAt Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Interim Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

Comments

Doctor-Owned Centers Spark Criticism, Scrutiny

quotesThis article in the Washington Post highlights an area of interest as we enter an era of health care…quotes